- Clinical trial results support progression of CGM+ toward regulatory submissions and scaled commercialization - Anticipating initiation of pivotal clinical trial in 2026 - Updated electronics architecture delivers significant improvement in glucose measurement accuracy, with a material reduction in MARD across multi-day wear - Multimodal sensing platform powered by advanced AI-native analytics to deliver personalized metabolic health insights - CGM+ next-generation modular device architecture designed to reduce cost and improve sustainability versus current market-leading CGMs - Company is positioning device to participate in fast-growing $15bn CGM market and adjacent sectors DUBLIN and WILSONVILLE, Ore., March 10, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a number of significant technical advancements in the development of its next-generation, finger-stick calibration-free Continuous Glucose Monitoring (CGM) system, CGM+, marking a major step toward bringing the technology to global markets.